{"name":"Xcovery Holdings, Inc.","slug":"xcovery-holdings-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"X-396 (ensartinib)","genericName":"X-396 (ensartinib)","slug":"x-396-ensartinib","indication":"Non-small cell lung cancer with ALK or ROS1 rearrangements","status":"phase_3"}]}],"pipeline":[{"name":"X-396 (ensartinib)","genericName":"X-396 (ensartinib)","slug":"x-396-ensartinib","phase":"phase_3","mechanism":"X-396 (ensartinib) is a potent and selective inhibitor of the anaplastic lymphoma kinase (ALK) and ROS1 kinases.","indications":["Non-small cell lung cancer with ALK or ROS1 rearrangements","Metastatic non-small cell lung cancer with ALK or ROS1 rearrangements"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPLW40cXZ3elBLal90Q3hpS1FwU0VzdmZGUWRFc3FIR1BOZ0w2cHlTbmkyb1pSYjE0R3hIX2pYZm9YWnh1UHczXzh6WWRQU3VsU2lkRWZhdXZCUmlLOHlTT0lVeS1HeEZnVjRiQU9HQ2hkM21BTlRkR2oxMUZ3aGJZMVlGcndWV3hqWHY2aDRZamdqVWtXeUhsanQ0UU85RjlJcVB3U1pFbWtBTGNnUVE?oc=5","date":"2024-12-19","type":"regulatory","source":"Fierce Pharma","summary":"Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer - Fierce Pharma","headline":"Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9GYTUwNG0xNUdNeG43UlkzVXA5WmR6THVtY1YzZVRIeGJwSGFpanVEeEJ4b08zM0d1ZXUzRWNqTURGVTFPcHpYTWFYY1U1clVrVGgyU0RLamZTZ0d3aXY1REs5QjVQdU93MWFtUk5ZMnpUOWs?oc=5","date":"2024-12-19","type":"regulatory","source":"The Pharma Letter","summary":"Xcovery’s Ensacove approved by FDA - The Pharma Letter","headline":"Xcovery’s Ensacove approved by FDA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxQN1JKcXBsSWg3NlVzUGhxSk5zYUJoSlViZE5YbF9KTUJ2akFUN20xZjB5dkVVSGc3UjhRN2lpdTFOWlpiTXl4NFliZHo0aldfMFBCVXZjZU9SMnl5LWJSVjRMcDVkWkh6UTRKQU5ITWlZNmNpejJxMm1xYmpwekJQUUpYcHdHdlh0NDBGdlZxeGJQZm9sNjZRT0F0TXRra2JBTEZuMVlfYnNvUGdqN1ZsZ205R1BWRnZndXFhUzRmNXpDQzkwQXRmY1doeWROWk9ZQWNsLUh0RE5HYklSVGc4cXdVQkdRRlUxeXRNeDFMVkN5YjM5ZWNn?oc=5","date":"2024-12-18","type":"regulatory","source":"businesswire.com","summary":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) - businesswire.com","headline":"FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPT3ctSUhsLWpYcHlzTkxYT2hMMnp4S3VJNHZNVTIzSEtMSG8xeWtQSU9Rd3JLd011Vlg1NTZ6NjlfaUdNeHhZdE1JbjlFZEx6UnR2dF95dldVX1ZrcFdqVnZZTE9mcXJUM2xtSU5XbkdTN20tdk96cldFYmZFSXNjV2pSaUFlMXJYU3pHOVZWdHBrY2l4bi1ibTVFRms2ajE4emlwcTY1dDJic1hCYnNBZUtLVEl4OGVUUXdFUFhrWGd3Z2s2MWVoQ2JOeUdJU0NkLWc5enpVYmJtdW5KVlBnWUJISXVSdzUyT0tIb0dn?oc=5","date":"2024-08-30","type":"pipeline","source":"prnewswire.com","summary":"ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveInsight - prnewswire.com","headline":"ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future Projections | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQcGlROVNBTTZGVUVvdHg1M3dpRFhqbXF3Z2VJSXhqU2VjMHB3R3pZcEMzMXp1TElxTVFkZU5KTW9taC1CMjNjaEtHTWp3X3N1bDRSVFpDTGhCTFQtVnhOZkJZS3lPbUJGOUNGSG94a1lzQmo4VG4weUVSQVkxSURtZGxWNXNQcmdBaG5WZUlCSmtPUUkyN1BPS0NCTHdEbV9TUTlnSEhzbFp4RFJTanFaXy1UMTdERTBSOTB3YmpGa09FUFFxSWplMkNqZS1GR0U2TFlBc0JYNnM5QmhuWEFuRERSR09kdw?oc=5","date":"2024-03-13","type":"regulatory","source":"businesswire.com","summary":"U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib - businesswire.com","headline":"U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPX05DS0JVYjM1TnZHTllFaGNTdEg4RV93X01ubnpHLW11VFBFWnhuTnY5dnpBVE53Y0FqZTE3Wm1EXzNZekEzTUZGRjBSYXNFMjI1XzZiZC1lOE9oZ0V5eTY3MGd4bFMzS2pDYmFGXzdBdEd4bUdGSzVJTzYySWdYVzl0Vkxtck5kODFaUm5yd2xJMXgzOE5SN1AwMklSQlRhQlhQalBRbGQtQ0E?oc=5","date":"2021-12-07","type":"deal","source":"citybiz","summary":"Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals - citybiz","headline":"Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOV1JyQm9MVktiT0M5bEx3cGRhaWdjZmV6dFh1Q1U5Z2U3LWs4UVF0cm1CNHVFQW4xV212Yi16WThsc2MxWE5BNXA3M1RhbUJjcWhqakhVQTBSdTRMZWd1UXdJQ2RpSWZ1OVJQMExBZVg2cEMzYVNKMWZXNXB6OTV1MURiVDJqWW12YVRFX3k3QUd1a3lad3VCQ2tMZkp2LXNQcHc5YjBNMENadw?oc=5","date":"2021-03-18","type":"pipeline","source":"BioSpace","summary":"Xcovery Announces the Appointment of Giovanni Selvaggi as Chief Executive Officer - BioSpace","headline":"Xcovery Announces the Appointment of Giovanni Selvaggi as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNYi1idVZjcVhOdW41UURYdFh1dkdsam5ZeDNXTldRaEFLUVhSN09jMlZ3NFpXdHNZLUdLZ0ZVOGJHSnJQVVZEMmc3XzZWWHJwM1E5cVk4cjVrRmVKM2c4THNmMWROcGlNZXlZb1AyZGFETmhnQThQTVlobXdTeEFqQXVXRXpVQTdoZGpwZzIxLWNoOGo3ZFdHeGt0V1EyNjRpZk91WXdsV3luaGhlTUtFbVFLcF9XRHlxTjRBM1dHdmRSVUdSc3cwZ1Y2NnZRRDBPLUh1bQ?oc=5","date":"2021-03-18","type":"pipeline","source":"businesswire.com","summary":"Xcovery Announces the Appointment of Giovanni Selvaggi as Chief Executive Officer - businesswire.com","headline":"Xcovery Announces the Appointment of Giovanni Selvaggi as Chief Executive Officer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}